Advisors Engaged to Advance Biomarker-Driven Clinical Program

BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – January 15, 2013) BioAegis Therapeutics announced that it has assembled a Critical Care Clinical Advisory Board comprised of world-recognized, highly experienced key opinion leaders. Initial members are:
Derek Angus, M.D., Professor and Chair, Critical Care Medicine and Professor, Medicine and Health Policy and Management, University of Pittsburgh School of Medicine
Atul Malhotra, M.D.,Associate Professor of Medicine, Harvard Medical School. Secretary-
Treasurer American Thoracic Society (2015-16 President)
Steven Opal, M.D.. Professor of Medicine, Brown University School of Medicine; Chief, Infectious Disease Division, Memorial Hospital of RI
B. Taylor Thompson, M.D., Professor of Medicine, Harvard Medical School; Director, Medical Intensive Care Unit, Massachusetts General Hospital

BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – November 10, 2012) Pursuant to the terms of the agreement with the Brigham and Women’s Hospital previously announced on May 11, 2011, BioAegis Therapeutics elected to exercise its option into an exclusive license to recombinant human plasma gelsolin technology.

BioAegis’ Patent Coverage Expands to Asia

Recombinant human plasma gelsolin has demonstrated efficacy against both gram positive and gram negative bacteria and this broad patent filing was recently granted in China. BioAegis is pursuing worldwide patent filings for infectious disease.

BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – August 30, 2012) Lester Kobzik M.D., BioAegis Scientific Advisor and collaborator from Harvard School of Public Health, has made important medical discoveries about plasma gelsolin’s role in boosting immune function to target a broad range of pathogens. Dr. Kobzik is pursuing work in secondary pneumonia under a $1 million NIH grant to support advancement of our plasma gelsolin work.

Company Requested to Submit White Papers Following IND

BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – July 15, 2012) BioAegis Therapeutics Inc. announced that it has presented its plasma gelsolin technology platform to scientists at the Biological Advanced Research Development Agency (BARDA). Data shared at the meeting demonstrated the ability of plasma to address biological threats, including radiation exposure and potential pandemics. TechWatch meetings enable industry participants to brief the agency on new and innovative technology. The meetings are applied for and granted if the technology is of high interest.